Biggest News Aggregation in the World
📰 Jon Patton News

Page 3 - Jon Patton News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Jon Patton. Real-time updates on events, politics, business and more.

Oncolytics Biotech's® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial

Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial If successful, new clinical study expected to supp...
Jon Patton Matt Coffey Timothy Mccarthy Thomas Heineman Julie Fleshman Securities Exchange

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel
United States Comunidad Autonoma De Cataluna Mecklenburg Vorpommern Bruxelles Capitale Timothy Mccarthy Aleix Prat

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Pelareorep-paclitaxel combination reduced risk of disease progression by 71% compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with... | June 5, 2023
United States Bruxelles Capitale Comunidad Autonoma De Cataluna Oncolytic Reovirus Pelareorep Matt Coffey Aleix Prat

Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced that it will host a key opinion leader webinar to discuss data from the randomized...
Bruxelles Capitale Comunidad Autonoma De Cataluna United States Institut Jules Bordet Jon Patton Timothy Mccarthy

Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

Key opinion leader webinar to take place on June 5, 2023 at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, May 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) announced
United States Comunidad Autonoma De Cataluna Bruxelles Capitale Davida Karnofsky Institut Jules Bordet Jon Patton

Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives =50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off
United States Oncolytic Reovirus Pelareorep Jon Patton Timothy Mccarthy Matt Coffey Thomas Heineman

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science